Eli Lilly ’s lasmiditan meets Phase III trial endpoints for migraine
Eli Lilly and Company has reported positive results from the Phase III SPARTAN clinical trial of lasmiditan for the acute treatment of migraines.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news